NCT05798117View on ClinicalTrials.gov

An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

September 9, 2026

Study Completion Date

September 9, 2026

Conditions
Systemic Lupus ErythematosusLupus Nephritis
Interventions
DRUG

YTB323

Single infusion of YTB323

Trial Locations (12)

1011

Novartis Investigative Site, Lausanne

3010

Novartis Investigative Site, Bern

3168

Novartis Investigative Site, Clayton

28009

Novartis Investigative Site, Madrid

33604

Novartis Investigative Site, Pessac

35294

Division of Rheumatology Immunology, Birmingham

55131

Novartis Investigative Site, Mainz

59037

Novartis Investigative Site, Lille

67091

Novartis Investigative Site, Strasbourg

75013

Novartis Investigative Site, Paris

79106

Novartis Investigative Site, Freiburg im Breisgau

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY